Scientists Propose 'Bodyoids' To Address Medical Research and Organ Shortage Challenges
Stanford University researchers have proposed creating "bodyoids" -- ethically sourced human bodies grown from stem cells without neural components for consciousness or pain sensation -- to revolutionize medical research and address organ shortages. In a new opinion piece published in MIT Technology Review, scientists Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi argue that recent advances in biotechnology make this concept increasingly plausible. The approach would combine pluripotent stem cells, artificial uterus technology, and genetic techniques to inhibit brain development. The researchers point to persistent shortages of human biological materials as a major bottleneck in medical progress. More than 100,000 patients currently await solid organ transplants in the US alone, while less than 15% of drugs entering clinical trials receive regulatory approval. These lab-grown bodies could potentially generate patient-specific organs that are perfect immunological matches, eliminate the need for lifelong immunosuppression, and provide personalized drug screening models. Read more of this story at Slashdot.
Stanford University researchers have proposed creating "bodyoids" -- ethically sourced human bodies grown from stem cells without neural components for consciousness or pain sensation -- to revolutionize medical research and address organ shortages. In a new opinion piece published in MIT Technology Review, scientists Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi argue that recent advances in biotechnology make this concept increasingly plausible. The approach would combine pluripotent stem cells, artificial uterus technology, and genetic techniques to inhibit brain development.
The researchers point to persistent shortages of human biological materials as a major bottleneck in medical progress. More than 100,000 patients currently await solid organ transplants in the US alone, while less than 15% of drugs entering clinical trials receive regulatory approval. These lab-grown bodies could potentially generate patient-specific organs that are perfect immunological matches, eliminate the need for lifelong immunosuppression, and provide personalized drug screening models.
Read more of this story at Slashdot.
